Research hotspots and frontiers of neoadjuvant therapy in triple-negative breast cancer: a bibliometric analysis of publications between 2002 and 2023

被引：10

作者：

Yang, Chuang ^{[1
]}

Liu, Hui ^{[2
]}

Feng, Xing ^{[1
,3
]}

Shi, Han ^{[1
]}

Jiang, Yuchan ^{[1
]}

Li, Junfeng ^{[1
]}

Tan, Jinxiang ^{[1
]}

机构：

[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Breast & Thyroid Surg, Chongqing, Peoples R China

[2] Chongqing Med Univ, Affiliated Hosp 2, Dept Breast & Thyroid Surg, Chongqing, Peoples R China

[3] Peoples Hosp Liangping Dist, Dept Hepatobiliary Breast & Thyroid Surg, Chongqing, Peoples R China

来源：

INTERNATIONAL JOURNAL OF SURGERY | 2024年 / 110卷 / 08期

关键词：

bibliometrics; frontiers; neoadjuvant therapy; triple-negative breast cancer; visualization; PATHOLOGICAL COMPLETE RESPONSE; LONG-TERM SURVIVAL; SYSTEMIC THERAPY; DOUBLE-BLIND; NODE BIOPSY; CHEMOTHERAPY; PEMBROLIZUMAB; OUTCOMES; SURGERY; METAANALYSIS;

D O I：

10.1097/JS9.0000000000001586

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Triple-negative breast cancer (TNBC) is a highly aggressive type of breast cancer with poor prognosis, and neoadjuvant therapy (NAT) has emerged as an important component in managing advanced-stage patients by providing surgical opportunities and improving survival outcomes. A search of publications on NAT for TNBC from 2002 to 2023 was conducted through the Web of Science core collection. A comprehensive bibliometric analysis was conducted on the data using CiteSpace, VOSviewer, and Bibliometrix. The analysis revealed a continuous and steady growth in the number of articles published in this field over the past 20 years. The United States has made significant contributions to this field, with The University of Texas MD Anderson Cancer Center publishing the most articles. Loibl, S. from Germany was found to be the most published author with 54 articles. Analysis of the journals showed that the Journal of Clinical Oncology is the most cited journal. Combined with the keyword co-occurrence analysis and clustering analysis, current research topic focuses on treatment regimens and disease prognosis. Dual-map overlay of the journals indicates that the research trend is gradually shifting from molecular biology and genetics to immunology and clinical research. Combination therapy, including immunotherapy, may be the future direction for NAT treatment of TNBC. Overall, this study provides valuable insights into the current research status, latest advancements, and emerging development trend of NAT for TNBC.

引用

页码：4976 / 4992

页数：17

共 111 条

[1] Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer [J].

Adams, S. ;

Dieras, V. ;

Barrios, C. H. ;

Winer, E. P. ;

Schneeweiss, A. ;

Iwata, H. ;

Loi, S. ;

Patel, S. ;

Henschel, V. ;

Chui, S. Y. ;

Rugo, H. S. ;

Emens, L. A. ;

Schmid, P. .

ANNALS OF ONCOLOGY, 2020, 31 (05) :582-589

[2] Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials [J].

Alberro, J. A. ;

Ballester, B. ;

Deulofeu, P. ;

Fabregas, R. ;

Fraile, M. ;

Gubern, J. M. ;

Janer, J. ;

Moral, A. ;

de Pablo, J. L. ;

Penalva, G. ;

Puig, P. ;

Ramos, M. ;

Rojo, R. ;

Santesteban, P. ;

Serra, C. ;

Sola, M. ;

Solarnau, L. ;

Solsona, J. ;

Veloso, E. ;

Vidal, S. ;

Abe, O. ;

Abe, R. ;

Enomoto, K. ;

Kikuchi, K. ;

Koyama, H. ;

Masuda, H. ;

Nomura, Y. ;

Ohashi, Y. ;

Sakai, K. ;

Sugimachi, K. ;

Toi, M. ;

Tominaga, T. ;

Uchino, J. ;

Yoshida, M. ;

Coles, C. E. ;

Haybittle, J. L. ;

Moebus, V. ;

Leonard, C. F. ;

Calais, G. ;

Garaud, P. ;

Collett, V. ;

Davies, C. ;

Delmestri, A. ;

Sayer, J. ;

Harvey, V. J. ;

Holdaway, I. M. ;

Kay, R. G. ;

Mason, B. H. ;

Forbe, J. F. ;

Franci, P. A. .

LANCET ONCOLOGY, 2018, 19 (01) :27-39

[3] bibliometrix: An R-tool for comprehensive science mapping analysis [J].

Aria, Massimo ;

Cuccurullo, Corrado .

JOURNAL OF INFORMETRICS, 2017, 11 (04) :959-975

[4] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Hurvitz, S. A. ;

Tolaney, S. M. ;

Loirat, D. ;

Punie, K. ;

Oliveira, M. ;

Brufsky, A. ;

Sardesai, S. D. ;

Kalinsky, K. ;

Zelnak, A. B. ;

Weaver, R. ;

Traina, T. ;

Dalenc, F. ;

Aftimos, P. ;

Lynce, F. ;

Diab, S. ;

Cortes, J. ;

O'Shaughnessy, J. ;

Dieras, V ;

Ferrario, C. ;

Schmid, P. ;

Carey, L. A. ;

Gianni, L. ;

Piccart, M. J. ;

Loibl, S. ;

Goldenberg, D. M. ;

Hong, Q. ;

Olivo, M. S. ;

Itri, L. M. ;

Rugo, H. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541

[5] Treatment landscape of triple-negative breast cancer - expanded options, evolving needs [J].

Bianchini, Giampaolo ;

De Angelis, Carmine ;

Licata, Luca ;

Gianni, Luca .

NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (02) :91-113

[6] Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial [J].

Boughey, Judy C. ;

Suman, Vera J. ;

Mittendorf, Elizabeth A. ;

Ahrendt, Gretchen M. ;

Wilke, Lee G. ;

Taback, Bret ;

Leitch, A. Marilyn ;

Kuerer, Henry M. ;

Bowling, Monet ;

Flippo-Morton, Teresa S. ;

Byrd, David R. ;

Ollila, David W. ;

Julian, Thomas B. ;

McLaughlin, Sarah A. ;

McCall, Linda ;

Symmans, W. Fraser ;

Le-Petross, Huong T. ;

Haffty, Bruce G. ;

Buchholz, Thomas A. ;

Nelson, Heidi ;

Hunt, Kelly K. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (14) :1455-1461

[7] Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline [J].

Brackstone, Muriel ;

Baldassarre, Fulvia G. ;

Perera, Francisco E. ;

Cil, Tulin ;

Mac Gregor, Mariana Chavez ;

Dayes, Ian S. ;

Engel, Jay ;

Horton, Janet K. ;

King, Tari A. ;

Kornecki, Anat ;

George, Ralph ;

SenGupta, Sandip K. ;

Spears, Patricia A. ;

Eisen, Andrea F. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (27) :3056-+

[8] A Bibliometric Analysis of Top-Cited Journal Articles in Obstetrics and Gynecology [J].

Brandt, Justin S. ;

Hadaya, Ola ;

Schuster, Meike ;

Rosen, Todd ;

Sauer, Mark, V ;

Ananth, Cande, V .

JAMA NETWORK OPEN, 2019, 2 (12) :E1918007

[9] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 [J].

Burstein, H. J. ;

Curigliano, G. ;

Thurlimann, B. ;

Weber, W. P. ;

Poortmans, P. ;

Regan, M. M. ;

Senn, H. J. ;

Winer, E. P. ;

Gnant, M. .

ANNALS OF ONCOLOGY, 2021, 32 (10) :1216-1235

[10] Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 [J].

Burstein, H. J. ;

Curigliano, G. ;

Loibl, S. ;

Dubsky, P. ;

Gnant, M. ;

Poortmans, P. ;

Colleoni, M. ;

Denkert, C. ;

Piccart-Gebhart, M. ;

Regan, M. ;

Senn, H. -J. ;

Winer, E. P. ;

Thurlimann, B. .

ANNALS OF ONCOLOGY, 2019, 30 (10) :1541-1557

← 1 2 3 4 5 6 7 8 9 10 →